Nickel(II) reacts with cephalosporins plus sulfathiazole (Hstz) to form the following mixed-ligand complexes of general formulae [Ni(L)(stz) ( , ; , ; L = monoanion of cefazolin , cephalothin , cefotaxime , ceftriaxone ) and [Ni( )(stz)]Cl (cefepime ), which were characterized by physicochemical and spectroscopic methods. Their spectra indicated that cephalosporins are acting as multidentate chelating agents, via the lactam carbonyl and carboxylate and N-azomoieties. The complexes are insoluble in water and common organic solvents but soluble in DMSO, where the [Ni( )(stz)]Cl complex is 1？:？1 electrolyte. They probably have polymeric structures. They have been screened for antibacterial activity, and the results are compared with the activity of commercial cephalosporins. 1. Introduction Cephalosporins are classed as β-lactam antibiotics, and they are widely used in clinical therapy for the treatment of severe infections, because of their antibacterial activity [1, 2]. Most common among several mechanisms by which bacteria develop resistance to β-lactam antibiotics is by elaboration of the enzyme β-lactamase, which hydrolyzes the β-lactam ring. A second mechanism is through alteration of penicillin-binding proteins (PBPs), which are found as both membrane-bound and cytoplasmic enzymes that catalyze cross-linking reactions in bacterial cell wall synthesis [3, 4]. PBPs are targets of β-lactam antibiotics, which interfere with cell wall synthesis by binding covalently to the catalytic site. Most bacterial species produce several PBPs, differing in molecular weight, affinity for binding β-lactam antibiotics, and enzymatic function (e.g., transpeptidase, carboxypeptidase, or endopeptidase). The PBPs are usually broadly classified into high-molecular-weight and low-molecular-weight categories [3, 4]. Prior to the availability and application of antibiotics for the control of diseases, sulfonamides were employed as effective chemotherapeutic agents for the prevention and cure of bacterial infections in humans [5, 6]. Certain microbes require p-aminobenzoic acid (PABA) in order to synthesize dihydrofolic acid, which is required to produce purines and ultimately nucleic acids. Sulfonamides, chemical analogs of PABA, are competitive inhibitors of dihydropteroate synthetase. The complex formation between metal ions and sulfa drugs has also been extensively studied with a view to establish the relationship and importance of metal-drug interactions [7–10]. The interaction of antibiotics with main and transition metal ions has attracted our attention and compelled us
References
[1]
A. A. Mederios, “Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics,” Clinical Infectious Diseases, vol. 24, no. 1, supplement, pp. S19–S45, 1997.
[2]
H. Bello, M. Dominguez, G. Gonzalez, et al., “In vitro activities of ampicillin, sulbactam and a combination of ampicillin and sulbactam against isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolated in Chile between 1990 and 1998,” Journal of Antimicrobial Chemotherapy, vol. 45, no. 5, pp. 712–713, 2000.
[3]
H. F. Chambers and M. Sachdeva, “Binding of β-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus,” Journal of Infectious Diseases, vol. 161, no. 6, pp. 1170–1176, 1990.
[4]
C. J. Hackbarth, T. Kocagoz, S. Kocagoz, and H. F. Chambers, “Point mutations in Staphylococcus aureus PBP 2 gene affect penicillin- binding kinetics and are associated with resistance,” Antimicrobial Agents and Chemotherapy, vol. 39, no. 1, pp. 103–106, 1995.
[5]
T. Kamimura, Y. Matsumoto, N. Okada, et al., “Ceftizoxime (FK 749), a new parenteral cephalosporin: in vitro and in vivo antibacterial activities,” Antimicrobial Agents and Chemotherapy, vol. 16, no. 5, pp. 540–548, 1979.
[6]
K. P. Fu and H. C. Neu, “Antibacterial activity of ceftizoxime, a β-lactamase-stable cephalosporin,” Antimicrobial Agents and Chemotherapy, vol. 17, no. 4, pp. 583–590, 1980.
[7]
J. Casanova, G. Alzuet, S. Ferrer, J. Borras, S. Garcia-Granda, and E. Perez-Carreno, “Metal complexes of sulfanilamide derivatives. Crystal structure of [Zn(sulfathiazole)2] · H2O,” Journal of Inorganic Biochemistry, vol. 51, no. 4, pp. 689–699, 1993.
[8]
J. Casanova, G. Alzuet, J. Borras, J. Latorre, M. Sanau, and S. Garcia-Granda, “Coordination behavior of sulfathiazole. Crystal structure of [Cu (sulfathiazole)(py)3Cl] superoxide dismutase activity,” Journal of Inorganic Biochemistry, vol. 60, no. 3, pp. 219–230, 1995.
[9]
J. Casanova, G. Alzuet, J. Borras, J. Timoneda, S. Garcia-Granda, and I. Candano- Gonzalez, “Coordination behavior of sulfathiazole. Crystal structure of dichloro- disulfathiazole ethanol Cu(II) complex. Superoxide dismutase activity,” Journal of Inorganic Biochemistry, vol. 56, no. 2, pp. 65–76, 1994.
[10]
J. Casanova, G. Alzuet, J. Borrás, and O. Carugo, “Crystal structures and superoxide dismutase mimetic activity of [CuL2(Him)2]·MeOH and [CuL2(mim)2]·H2O [HL = 4-amino-N-(thiazol-2-yl)benzenesulfonamide, Him = imidazole, mim = N-methylimidazole],” Journal of the Chemical Society-Dalton Transactions, no. 11, pp. 2239–2244, 1996.
[11]
J. R. Anacona and H. Rodriguez, “Metalloantibiotics: synthesis and antibacterial activity of cefepime metal complexes,” Journal of Coordination Chemistry, vol. 62, no. 13, pp. 2212–2219, 2009.
[12]
J. R. Anacona and G. Da Silva, “Synthesis and antibacterial activity of cefotaxime metal complexes,” Journal of the Chilean Chemical Society, vol. 50, no. 2, pp. 447–450, 2005.
[13]
J. R. Anacona and P. Alvarez, “Synthesis and antibacterial activity of metal complexes of cefazolin,” Transition Metal Chemistry, vol. 27, no. 8, pp. 856–860, 2002.
[14]
J. R. Anacona and J. Serrano, “Synthesis and antibacterial activity of metal complexes of cephalothin,” Journal of Coordination Chemistry, vol. 56, no. 4, pp. 313–320, 2003.
[15]
J. R. Anacona and A. Rodriguez, “Synthesis and antibacterial activity of ceftriaxone metal complexes,” Transition Metal Chemistry, vol. 30, no. 7, pp. 897–901, 2005.
[16]
J. R. Anacona and L. Brito, “In vitro cytotoxicity and antibacterial activities of cephalosporin Tin(II) complexes,” Latin American Journal of Pharmacy, vol. 30, no. 1, p. 172, 2011.
[17]
D. Liu and K. Kwasniewska, “An improved agar plate method for rapid assessment of chemical inhibition to microbial populations,” Bulletin of Environmental Contamination and Toxicology, vol. 27, no. 1, pp. 289–294, 1981.
[18]
S. A. Khan, N. Nishat, S. Parveen, and R. Rasool, “Preparation, spectral and biological investigation of formaldehyde-based ligand containing piperazine moiety and its various polymer metal complexes,” Spectrochimica Acta Part A, vol. 81, pp. 290–395, 2011.
[19]
A. V. Nikolaev, V. A. Logvinenko, and L. T. Myachina, Thermal Analysis, vol. 2, Academic Press, New York, NY, USA, 1969.
[20]
W. J. Geary, “The use of conductivity measurements in organic solvents for the characterisation of coordination compounds,” Coordination Chemistry Reviews, vol. 7, no. 1, pp. 81–122, 1971.
[21]
K. Nakamoto, Infrared and Raman Spectra of Inorganic and Coordination Compounds, John Wiley & Sons, New York, NY, USA, 4th edition, 1986.
[22]
G. Socrates, Infrared Characteristic Group Frequencies, John Wiley & Sons, London, UK, 1980.
[23]
K. A. R. Salib, A. A. Saleh, S. Abu El-Wafa, and H. F. O. El-Shafiy, “Preparation and characterization of novel asymmetrical Schiff-base ligands derived from 2-methyl-7-formyl-8-hydroxyquinoline and their metal complexes,” Journal of Coordination Chemistry, vol. 56, no. 4, pp. 283–298, 2003.
[24]
R. Srinivasan, I. Sougandi, R. Venkatesan, and P. Sambasiva Rao, “Synthesis and room temperature single crystal EPR studies of a dinickel complex having an {Ni2(μ-phenoxide)2}2+ unit supported by a macrocyclic ligand environment [Ni2(L)2(OClO3)2] [L = 2-[(4-methyl-pyridin-2-ylimino)-methyl]-phenol],” Proceedings of the Indian Academy of Sciences, vol. 115, no. 2, pp. 91–102, 2003.
[25]
E. Mosiniewicz-Szablewska, A. ？lawska-Waniewska, K. ？wiatek, N. Nedelko, and M. Golebiewski, “Magnetic properties of Ni-complexes in a hydrazone structure,” Physica Status Solidi (A) Applied Research, vol. 196, no. 1, pp. 213–216, 2003.
[26]
G. C. Franchini, A. Giusti, C. Preti, L. Tassi, and P. Zannini, “Coordinating ability of methylpiperidine dithiocarbamates towards platinum group metals,” Polyhedron, vol. 4, no. 9, pp. 1553–1558, 1985.
[27]
C. C. Hadjikostas, G. A. Katsoulos, and S. K. Shakhatreh, “Synthesis and spectral studies of some new palladium(II) and platinum(II) dithiocarbimato complexes. Reactions of bases with the corresponding N-alkyldithiocarbamates,” Inorganica Chimica Acta, vol. 133, no. 1, pp. 129–132, 1987.
[28]
M. Castillo, J. J. Criado, B. Macias, and M. V. Vaquero, “Chemistry of dithiocarbamate derivatives of amino acids. I. Study of some dithiocarbamate derivatives of linear α-amino acids and their nickel(II) complexes,” Inorganica Chimica Acta, vol. 124, no. 3, pp. 127–132, 1986.
[29]
D. X. West, A. K. El-Sawaf, and G. A. Bain, “Metal complexes of N(4)-substituted analogs of the antiviral drug methisazone 1-methylisatin thiosemicarbazone,” Transition Metal Chemistry, vol. 23, pp. 1–6, 1998.
[30]
O. A. El-Gammal, G. A. El-Reash, and S. F. Ahmed, “Structural, spectral, thermal and biological studies on 2-oxo-N′-((4-oxo-4H-chromen-3-yl)methylene)-2-(phenylamino)acetohydrazide (H2L) and its metal complexes,” Journal of Molecular Structure, vol. 1007, pp. 1–10, 2012.
[31]
S. A. Sadeek, H. W. El-Shwiniy, W. A. Zordok, and E. Kotb, “Spectroscopic studies, thermal analyses and biological evaluation of new V(IV), Zr(IV) and U(VI) moxifloxacin complexes,” Journal of Molecular Structure, vol. 192, p. 1006, 2011.
[32]
J. R. Anacona and C. Toledo, “Synthesis and antibacterial activity of metal complexes of ciprofloxacin,” Transition Metal Chemistry, vol. 26, no. 1-2, pp. 228–231, 2001.
[33]
I. Turel, L. Golic, P. Bukovec, and M. Gubina, “Antibacterial tests of bismuth (III) -quinolone (Ciprofloxacin, cf) compounds against helicobacter pylori and some other bacteria,” Journal of Inorganic Biochemistry, vol. 71, pp. 53–60, 1998.
[34]
I. Turel, I. Leban, and N. Bukovec, “Crystal structure and characterization of the bismuth(III) compound with quinolone family member (ciprofloxacin). Antibacterial study,” Journal of Inorganic Biochemistry, vol. 66, no. 4, pp. 241–245, 1997.
[35]
H. F. A. El-Halim, G. G. Mohamed, M. M. I. El-Dessouky, and W. H. Mahm, “Ligational behaviour of lomefloxacin drug towards Cr(III), Mn(II), Fe(III), Co(II), Ni(II), Cu(II), Zn(II), Th(IV) and UO2(VI) ions: synthesis, structural characterization and biological activity studies,” Spectrochimica Acta A, vol. 82, pp. 8–19, 2011.
